Dingfeng Fang, Huihe Chen, Hui Geng, Xiahuan Chen, Meilin Liu
{"title":"预测心源性休克患者生存的nomogram发展与验证。","authors":"Dingfeng Fang, Huihe Chen, Hui Geng, Xiahuan Chen, Meilin Liu","doi":"10.3389/fcvm.2025.1538395","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is currently a lack of easy-to-use tools for assessing the severity of cardiogenic shock (CS) patients. This study aims to develop a nomogram for evaluating severity in CS patients regardless of the underlying cause.</p><p><strong>Methods and results: </strong>The MIMIC-IV database was used to identify 1,923 CS patients admitted to the ICU. A multivariate Cox model was developed in the training cohort (70%) based on LASSO regression results. Factors such as age, systolic blood pressure, arterial oxygen saturation, hemoglobin, serum creatinine, blood glucose, arterial pH, arterial lactate, and norepinephrine use were incorporated into the final model. This model was visualized as a Cardiogenic Shock Survival Nomogram (CSSN) to predict 30-day survival rates. The model's c-statistic was 0.75 (95% CI: 0.73-0.77) in the training cohort and 0.73 (95% CI: 0.70-0.77) in the validation cohort, demonstrating good predictive accuracy. The AUC of the CSSN for 30-day survival probabilities was 0.76 in the training cohort and 0.73 in the validation cohort. Calibration plots showed strong concordance between predicted and actual survival rates, and decision curve analysis (DCA) affirmed the model's clinical utility. The CSSN outperformed the Cardiogenic Shock Score (CSS) in various metrics, including c-statistic, time-dependent ROC, calibration plots, and DCA (c-statistic: 0.75 vs. 0.72; AUC: 0.76 vs. 0.73, <i>P</i> < 0.01 by Delong test). Subgroup analysis confirmed the model's robustness across both AMI-CS and non-AMI-CS subgroups.</p><p><strong>Conclusions: </strong>The CSSN was developed to predict 30-day survival rates in CS patients irrespective of the underlying cause, showing good performance and potential clinical utility in managing CS.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1538395"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069261/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development and validation of a nomogram for predicting survival in patients with cardiogenic shock.\",\"authors\":\"Dingfeng Fang, Huihe Chen, Hui Geng, Xiahuan Chen, Meilin Liu\",\"doi\":\"10.3389/fcvm.2025.1538395\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is currently a lack of easy-to-use tools for assessing the severity of cardiogenic shock (CS) patients. This study aims to develop a nomogram for evaluating severity in CS patients regardless of the underlying cause.</p><p><strong>Methods and results: </strong>The MIMIC-IV database was used to identify 1,923 CS patients admitted to the ICU. A multivariate Cox model was developed in the training cohort (70%) based on LASSO regression results. Factors such as age, systolic blood pressure, arterial oxygen saturation, hemoglobin, serum creatinine, blood glucose, arterial pH, arterial lactate, and norepinephrine use were incorporated into the final model. This model was visualized as a Cardiogenic Shock Survival Nomogram (CSSN) to predict 30-day survival rates. The model's c-statistic was 0.75 (95% CI: 0.73-0.77) in the training cohort and 0.73 (95% CI: 0.70-0.77) in the validation cohort, demonstrating good predictive accuracy. The AUC of the CSSN for 30-day survival probabilities was 0.76 in the training cohort and 0.73 in the validation cohort. Calibration plots showed strong concordance between predicted and actual survival rates, and decision curve analysis (DCA) affirmed the model's clinical utility. The CSSN outperformed the Cardiogenic Shock Score (CSS) in various metrics, including c-statistic, time-dependent ROC, calibration plots, and DCA (c-statistic: 0.75 vs. 0.72; AUC: 0.76 vs. 0.73, <i>P</i> < 0.01 by Delong test). Subgroup analysis confirmed the model's robustness across both AMI-CS and non-AMI-CS subgroups.</p><p><strong>Conclusions: </strong>The CSSN was developed to predict 30-day survival rates in CS patients irrespective of the underlying cause, showing good performance and potential clinical utility in managing CS.</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":\"12 \",\"pages\":\"1538395\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069261/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2025.1538395\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1538395","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:目前缺乏易于使用的工具来评估心源性休克(CS)患者的严重程度。本研究的目的是开发一个nomogram来评估CS患者的严重程度,而不考虑潜在的病因。方法和结果:使用MIMIC-IV数据库对1923例入住ICU的CS患者进行识别。基于LASSO回归结果,在培训队列(70%)中建立多变量Cox模型。将年龄、收缩压、动脉血氧饱和度、血红蛋白、血清肌酐、血糖、动脉pH、动脉乳酸、去甲肾上腺素使用情况等因素纳入最终模型。该模型被可视化为心源性休克生存图(csn)来预测30天生存率。模型的c统计量在训练组为0.75 (95% CI: 0.73-0.77),在验证组为0.73 (95% CI: 0.70-0.77),具有较好的预测准确性。训练组csn的30天生存概率AUC为0.76,验证组为0.73。校正图显示预测生存率与实际生存率具有较强的一致性,决策曲线分析(DCA)证实了该模型的临床实用性。csn在各种指标上优于心源性休克评分(CSS),包括c-统计量、时间相关ROC、校准图和DCA (c-统计量:0.75 vs 0.72;AUC: 0.76 vs. 0.73, P结论:csn用于预测CS患者的30天生存率,与潜在病因无关,在CS治疗中表现出良好的性能和潜在的临床应用价值。
Development and validation of a nomogram for predicting survival in patients with cardiogenic shock.
Background: There is currently a lack of easy-to-use tools for assessing the severity of cardiogenic shock (CS) patients. This study aims to develop a nomogram for evaluating severity in CS patients regardless of the underlying cause.
Methods and results: The MIMIC-IV database was used to identify 1,923 CS patients admitted to the ICU. A multivariate Cox model was developed in the training cohort (70%) based on LASSO regression results. Factors such as age, systolic blood pressure, arterial oxygen saturation, hemoglobin, serum creatinine, blood glucose, arterial pH, arterial lactate, and norepinephrine use were incorporated into the final model. This model was visualized as a Cardiogenic Shock Survival Nomogram (CSSN) to predict 30-day survival rates. The model's c-statistic was 0.75 (95% CI: 0.73-0.77) in the training cohort and 0.73 (95% CI: 0.70-0.77) in the validation cohort, demonstrating good predictive accuracy. The AUC of the CSSN for 30-day survival probabilities was 0.76 in the training cohort and 0.73 in the validation cohort. Calibration plots showed strong concordance between predicted and actual survival rates, and decision curve analysis (DCA) affirmed the model's clinical utility. The CSSN outperformed the Cardiogenic Shock Score (CSS) in various metrics, including c-statistic, time-dependent ROC, calibration plots, and DCA (c-statistic: 0.75 vs. 0.72; AUC: 0.76 vs. 0.73, P < 0.01 by Delong test). Subgroup analysis confirmed the model's robustness across both AMI-CS and non-AMI-CS subgroups.
Conclusions: The CSSN was developed to predict 30-day survival rates in CS patients irrespective of the underlying cause, showing good performance and potential clinical utility in managing CS.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.